| Patents for C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (26,637) |
|---|
| 12/12/2001 | EP1162270A2 Phagemids coexpressing a surface receptor and a surface heterologous protein |
| 12/12/2001 | EP1162267A2 Plant virus vector, plasmid, process for expression of foreign gene and process for obtaining foreign gene product |
| 12/12/2001 | EP1161958A1 A method for the inactivation of viruses in biological liquids |
| 12/12/2001 | EP1161953A2 IBDV strain for in OVO administration |
| 12/12/2001 | EP1161537A1 Non-spreading pestivirus |
| 12/12/2001 | EP0783586B1 An attenuated vaccination and gene-transfer virus, a method to make the virus and a pharmaceutical composition comprising the virus |
| 12/12/2001 | EP0651789B1 Method for preventing zoster and alleviating varicella related post-herpetic neuralgia |
| 12/12/2001 | CN1076052C Nucleic acid sequences, carrier containing them, medical compositions and usage for treatment |
| 12/11/2001 | US6329200 Plasmids for construction of eukaryotic viral vectors |
| 12/11/2001 | US6329199 A vector resistant to inactivation by human serum, produced in cells containing retroviral envelope protein sequence from feline endogenous virus, long terminal repeats sequences, signal and packaging sequences; for effective gene therapy |
| 12/11/2001 | US6328976 Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor |
| 12/11/2001 | US6328975 Recombinant swinepox virus |
| 12/11/2001 | US6328958 Deleted adenovirus vectors and methods of making and administering the same |
| 12/11/2001 | CA2162132C Hepatitis b virus mutants, reagents and methods for detection |
| 12/11/2001 | CA2066053C Recombinant retroviruses delivering vector constructs to target cells |
| 12/09/2001 | CA2349960A1 Ibdv strain for in ovo administration |
| 12/09/2001 | CA2309379A1 Viral variants and uses therefor |
| 12/06/2001 | WO2001092552A2 Method for the purification of alphavirus replicon particles |
| 12/06/2001 | WO2001092551A2 Duplexed parvovirus vectors |
| 12/06/2001 | WO2001092549A2 Method and composition for targeting an adenoviral vector |
| 12/06/2001 | WO2001092547A2 Modified bovine adenovirus having altered tropism |
| 12/06/2001 | WO2001092486A1 Serotype chimeric ibdv strains |
| 12/06/2001 | WO2001092464A2 Therapeutic vaccine preparation and treatment for hiv viral infection |
| 12/06/2001 | WO2001092299A2 Adenovirus particles with mutagenized fiber proteins |
| 12/06/2001 | WO2001091790A1 Vaccine composition |
| 12/06/2001 | WO2001091536A2 Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens |
| 12/06/2001 | WO2000077233A3 Complement-resistant non-mammalian dna viruses and uses thereof |
| 12/06/2001 | US20010049145 Hepatitis B virus vectors for gene therapy |
| 12/06/2001 | US20010049137 DNA fragments derived from the genomic DNA of HPV-33, including recombinant vectors, which cells are replicated in host cells and expressed as immunogenic proteins; diagnosis of tumors; antibodies to detect viral infections |
| 12/06/2001 | US20010049136 Deletion of: all or part of the E1A regions, the E1B region coding for the early proteins, E2 or E4 regions, the E1a region and encapsidation region; gene therapy |
| 12/06/2001 | US20010049089 Storage and maintenance of blood products including red blood cells and platelets |
| 12/06/2001 | US20010048928 Herpesvirus particles comprising fusion protein and their preparation and use |
| 12/06/2001 | US20010048920 Reovirus for the treatment of neoplasia |
| 12/06/2001 | US20010048919 Virus clearance of neoplastic cells from mixed cellular compositions |
| 12/06/2001 | CA2410981A1 Adenovirus particles with mutagenized fiber proteins |
| 12/06/2001 | CA2410665A1 Modified bovine adenovirus having altered tropism |
| 12/06/2001 | CA2410543A1 Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens |
| 12/05/2001 | EP1159969A1 Composition vaccinale |
| 12/05/2001 | EP1159968A1 Attenuated strains of Dengue virus and their use in a vaccine composition |
| 12/05/2001 | EP1159440A2 Compositions and methods for recombinant adeno-associated virus production |
| 12/05/2001 | EP1159439A2 Enhanced system for construction of adenovirus vectors |
| 12/05/2001 | EP1159419A1 Promotion or inhibition of angiogenesis and cardiovascularization |
| 12/05/2001 | EP1159405A2 Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine |
| 12/05/2001 | EP1159297A2 Hiv related peptides |
| 12/05/2001 | EP0763114B1 Hepatitis g virus and molecular cloning thereof |
| 12/05/2001 | EP0663953B1 Phagemids coexpressing a surface receptor and a surface heterologous protein |
| 12/05/2001 | CN1325450A Adenovirus-mediated gene therapy |
| 12/05/2001 | CN1324660A Static water pressure deactivation and nanometer techn. treatment process of influenza virus to prepare lytic vaccine |
| 12/04/2001 | US6326183 Chromatographically concentrated baculovirus and methods |
| 12/04/2001 | CA2110703C Process and culture medium for the production of cells infected by a multiple sclerosis associated virus |
| 12/04/2001 | CA2087270C Modified baculovirus, method for obtaining it, and expression vectors obtained from said baculovirus |
| 12/04/2001 | CA2053829C Vaccines against equine herpesviruses and the preparation thereof |
| 12/04/2001 | CA2024253C Entities for cancer therapy |
| 11/29/2001 | WO2001090363A1 Chimeric arterivirus-like particles |
| 11/29/2001 | WO2001090340A2 Assembly of large viral genomes and chromosomes from subclones |
| 11/29/2001 | WO2001090302A2 Compositions and methods for production of rna viruses and rna virus-based vector particles |
| 11/29/2001 | WO2001089559A2 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine |
| 11/29/2001 | WO2001044458A3 Bovine immunodeficiency virus (biv) based vectors |
| 11/29/2001 | WO2001042445A3 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS |
| 11/29/2001 | WO2001027304A3 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| 11/29/2001 | WO2001025433A3 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 11/29/2001 | WO2001000846A3 Linoleate isomerase |
| 11/29/2001 | US20010046662 Method of inactivating pathogens in a red blood cell-containing composition |
| 11/29/2001 | US20010046500 Administering a vaccine in ovo to a fertile egg containing an embryo of the chicken and wherein the vaccine comprises an immunogenically effective amount of a live, avirulent strain of infectious bronchitis virus to treat infectious bronchitis |
| 11/29/2001 | US20010046450 Irradiation of blood with type c ultraviolet light, deactivating viruses |
| 11/29/2001 | CA2409874A1 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine |
| 11/28/2001 | EP1157123A1 Stable recombinant influenza viruses free of helper viruses |
| 11/28/2001 | EP1157121A1 Prrsv vaccines |
| 11/28/2001 | EP1157103A2 Production of helper dependent adenovirus vectors based on use of endonucleases |
| 11/28/2001 | EP1156813A2 Reovirus for the treatment of cellular proliferative disorders |
| 11/28/2001 | EP0698108B1 Adenoviral vectors of animal origin and use thereof in gene therapy |
| 11/27/2001 | US6323031 Lentiviral vectors derived from SIVagm, methods for their preparation and their use for gene transfer into mammalian cells |
| 11/27/2001 | US6323024 Plasmids for the expression of heterologus genes; for use in treatment and prevention of viral diseases |
| 11/27/2001 | US6323019 Design of novel highly efficient HIV based packaging systems for gene therapy |
| 11/27/2001 | US6322967 Recombinant tryptophan mutants of influenza |
| 11/27/2001 | US6322964 Synthetic HIV-2 gag and env oligopeptides reactive with HIV-2 specific antibodies |
| 11/27/2001 | US6322795 Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses |
| 11/27/2001 | US6322793 Replacement of gene 50 glycoprotein with foreign genetic material |
| 11/27/2001 | US6322792 Gamma-2 herpes viruses like kaposi's sarcoma-associated herpes virus useful in modulating persistence of heterologous dna; gene therapy |
| 11/27/2001 | US6322781 Production of recombinant baculoviruses |
| 11/27/2001 | US6322780 Marek's disease virus vaccines for protection against Marek's disease |
| 11/22/2001 | WO2001088203A1 Cloning of rhadinovirus genome and methods for its use |
| 11/22/2001 | WO2001088141A2 Synthetic gagpol genes and their uses |
| 11/22/2001 | WO2001087066A1 Vaccines, immunotherapeutics and methods for using the same |
| 11/22/2001 | WO2001023597A9 Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus |
| 11/22/2001 | WO2001019380A3 Oncolytic virus |
| 11/22/2001 | WO2001018169A3 Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases |
| 11/22/2001 | WO2001007637B1 Conditionally controlled, attenuated hiv vaccine |
| 11/22/2001 | US20010044526 Water soluble polymer backbone such as polyethylene glycol, endcapped with a N-maleimidyl moiety without using a linker; conjugated peptides, proteins, nucleotides and drugs |
| 11/22/2001 | US20010044149 Transfer of heterologous gene sequences into cells using equine infectious anemia virus-derived vectors for gene delivery |
| 11/22/2001 | US20010044148 EBV-infected stomach cancer cell line |
| 11/22/2001 | US20010044146 Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins |
| 11/22/2001 | US20010044133 Phage-dependent super-production of biologically active protein and peptides |
| 11/22/2001 | US20010043924 Attaching to the bacteriophage surfaces a polymer, e.g., polyoxyethylene glycol, to mask and block the phage surface antigens; longer half-life; immunology; bactericides |
| 11/22/2001 | US20010043921 A retroviral vector of a heterologous nucleic acid sequence as well as at least one sequence allowing site-specific integration of the sequence into a non-coding region of a genome; gene therapy of genetic defects; viricides |
| 11/22/2001 | US20010043917 Bacteriophage modified by serial passageing or genetic engineering so the modified bacteriophage will remain active in the body for a longer time than the wild-type phage; infections |
| 11/22/2001 | US20010043916 Purification of encapsuated viruses from a cell culture by lysing the culture containing encapsulated virus, filtering using diatomaceous earth or anionic cellulose filter aids, concentrating and diafiltering the filtrate several times |
| 11/22/2001 | DE10021433A1 Antiviral autovaccine, useful e.g. for treating virus-induced tumors or Crohn's disease, obtained by heating tissue containing viruses and antigens in presence of protein crosslinking agent |
| 11/22/2001 | CA2408433A1 Synthetic gagpol genes and their uses |
| 11/22/2001 | CA2408403A1 Vaccines, immunotherapeutics and methods for using the same |